ERBB2 and cancer: We also studied the link between TP53 status and pCR in TNBC and HER2 cancers stratified for the type of chemotherapy (carboplatin-containing vs control) as well as clinico-pathological factors (age, grade, cT, cN, hormone receptor status in HER2-positive disease), PIK3CA mutations, and LPBC subtype.